Special Issue "The Role of Hemagglutinin in Influenza Viruses Infection"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2018) | Viewed by 20011
Interests: antimicrobial resistance; system pharmacology; antibiotics discovery and development
Special Issues, Collections and Topics in MDPI journals
This Special Issue of Vaccines is aimed at the role of hemagglutinin (HA) in influenza virus infection. The primary function of HA is to initiate internalization of the virus into the host cell by binding to host sialic acid receptors attached to membrane glycoproteins, glycophospholipids and proteoglycans. For human-to-human transmission, viral HA must efficiently bind to human cell surface receptors and possess the integral proteins that enable it to efficiently replicate in the cells of the human upper respiratory tract. The HA glycoprotein is the principal surface antigen on the influenza virus, and, as such, is a major target for neutralizing antibodies. Antigenic drift mutations that produce amino acid substitutions in HA allow influenza viruses to escape immune surveillance and cause seasonal influenza outbreaks. Epitope mapping using neutralizing monoclonal antibodies helps define mechanisms of antigenic drift, neutralizing escape and can facilitate pre-pandemic vaccine design. The contributions in this Special Issue are expected to provide much needed insights into the multi-faceted role of this complex surface protein in the transmission and infectivity of influenza viruses.
A/Prof. Dr. Tony Velkov
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Virus hemagglutinin